Daniel Rehal

Why do “snake oil” salespeople still exist within rare, but visible pockets of the BioPharma industry? People with questionable ethics have swindled patients, put people’s health at risk, and have garnered hundreds of millions of dollars in profits, only to leave many patients desperate, feeling ripped-off, and angry at an Read more…

With the advent of COVID several years ago, medical communications companies and BioPharma companies alike have had to adapt to a more distributed workforce, mitigate personnel burnout, work to retain top talent, and navigate uncertainty with client demands. At the same time, virtual events are leveling out and demand for Read more…

When my brother-in-law, Nick was 39, he was diagnosed with late-stage liver cancer. At the University of Minnesota Medical Center, his team of providers told him to go home and spend his last 6 to 12 months as comfortable as possible and prepare for the end of his life. At Read more…

A discussion on povidone-iodine treatments and their effect on viruses such as COVID-19 In the first of the Vision2Voice KOL Spotlight in Medicine Video Series, President Dan Rehal sits down with Dr. Wallace Duff to talk about his work in the otolaryngology field, specifically related to the prevention of COVID-19 Read more…

In a recent blog article we discussed the paradigm shift in speaker training program execution. Specifically the migration from live to virtual, hybrid and on-demand speaker training programs. Although the tactical implementation of these programs has changed, one critical aspect has not, and that is how speakers communicate with their audiences.   It doesn’t Read more…

COVID-19 has reintroduced Americans to the value of the Biopharma industry; to save and to improve the quality of human lives. Good things have already come and great things are about to erupt. It seems like everything has changed. In actuality, none of this is anything new for Biopharma. Do Read more…

Nine months after the Office of Inspector General’s (OIG) November 2020 Special Fraud Alert: Speaker Programs was published, on August 6, 2021, PhRMA issued a statement addressing an update to the PhRMA Code on Interactions with Health Care Professionals. Effective January 1, 2022, PhRMA updated its principles relating to company-sponsored speaker programs and clarified other provisions of the PhRMA Code.   Read more…

The OIG’s Special Fraud Alert raised concerns towards some characteristics of speaker programs that may be considered risky. These programs, however, are necessary to educate healthcare professionals (HCPs) through Peer-to-Peer (P2P) educational strategies. When conducting P2P speaker programs, you can avoid some of the risks flagged by the OIG, and Read more…

So much has happened in the last few months in our industry especially in light of the OIG’s Special Fraud Alert on Speaker Programs that was issued toward the end of the year. I want to really get into some of those nuts and bolts, talk about what the OIG is telling us with Read more…

As you can imagine, 2020 saw a huge reduction in speaker dinner programs due to COVID-19. The Office of Inspector General (OIG) and the Department of Justice (DOJ) took the opportunity to let biopharma know that these programs remain risky. In its most recent guidance, it stated, “Companies should assess Read more…